James M. Rossetti, DO, discusses the utility of JAK inhibitors in myeloproliferative neoplasms.
James M. Rossetti, DO
Advertisement
Articles by James M. Rossetti, DO
James M. Rossetti, DO, discusses the FDA’s decision to grant momelotinib a fast track designation for use in patients with intermediate- or high-risk myelofibrosis who previously received a JAK inhibitor.
James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.
James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.
James M. Rossetti, DO, hematologist, UPMC Hillman Cancer Center, discusses risk stratification in myeloproliferative neoplasms (MPNs).
Advertisement
Latest Updated Articles
Dr. Rossetti on Risk Stratification in Myeloproliferative NeoplasmsPublished: August 20th 2019 | Updated:
Dr. Rossetti on Symptom Management for Patients With MPNsPublished: February 22nd 2020 | Updated:
Dr. Rossetti on Symptom Management for MPNsPublished: February 27th 2020 | Updated:
Dr. Rossetti on the Fast Track Designation of Momelotinib in MyelofibrosisPublished: April 10th 2020 | Updated:
Dr. Rossetti on the Utility of JAK Inhibitors in MPNsPublished: April 22nd 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5